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1. Introduction 
In this chapter, we focus on the effects of glycosylation in the cell biology of an amyloid, 
specifically in melanocytic cells. The actual operational definition of amyloid is that amyloid 
fibers display the cross-β fiber diffraction pattern, which is the basis of fiber formation, that 
leads to aggregation of misfolded proteins [1]. Under this concept, classical disease-
associated amyloids such as amyloid β-peptide (Ab) with Alzheimer’s disease join other 
non-disease associated or functional amyloids such as PMEL/Pmel17/gp100/silver (herein 
referred to as PMEL), which is involved in the deposition of melanin [2-4]. Early reports 
suggested that two domains inside PMEL are contributors to fibril formation [5]. Today, 
unequivocal evidence recognizes that the so called repeat (RPT) domain is the only region 
capable to form amyloid fibrils in vivo and in vitro [6-8]. Unlike disease-associated amyloids, 
functional amyloids are the product of coordinated and regular cellular processes that 
ensure that amyloidogenesis does not result in cell damage or death [2;9]. Several reports 
have indicated the role of post-translational modifications, specifically glycosylation, in the 
protein aggregation that leads either to neurodegeneration [10;11] or physiological amyloid 
deposition [12]. In Alzheimer’s disease, a cytosolic phosphoprotein called Tau, is 
abnormally phosphorylated [13]. The reason for this was attributed to an overall decrease in 
O-GlcNAcylation, a novel type of O-glycosylation by which the monosaccharide β-N-
acetylglucosamine (GlcNAc) attaches to serine /threonine residues via an O-linked 
glycosidic bond. O-glycosylated tau protein aggregates which leads to the formation of 
neurofibrillary tangles leading to toxicity and neuron death [13;14]. The aberrant deposition 
of proteins as cellular inclusions or plaques in the form of amyloid fibrils is a characteristic 
hallmark of all amyloid diseases (or amyloidosis) and of the so-called conformational 
diseases. Additionally, the β-amyloid precursor protein (βAPP) has also been found to be 
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modified in its cytoplasmic domain by both phosphorylation and glycosylation [15]. Large 
glycosylated secreted (βAPP) derivates are present in human cerebrospinal fluid, in brain, 
and in conditioned cell culture medium. 
Despite the vast number of reports and clinical studies conducted to date, 
neurodegeneration and amyloid formation are still one of the least understood processes, 
which is mostly due to the complex nature of molecular interactions as well as the 
challenging properties of naturally aggregating systems. In particular, the low solubility of 
the proteins involved, their tendency to aggregate and their difficult synthesis/isolation in 
vivo. In this chapter, we detail the influence of glycosylation in the formation of functional 
amyloid, specifically for PMEL. The study of this type of amyloid raises the question on why 
these amyloids are non-toxic and whether there are lessons to be learned related with the 
cellular management of these amyloids that could be used to understand and possibly alter 
the detrimental effects of disease-associated amyloids.  
2. Melanosomes and the functional amyloid PMEL  
The ability to form pigment or melanin requires that the melanocyte handle the biochemical 
steps it takes in a safe and controlled environment. In many organisms, melanocytes build a 
specialized organelle called the melanosome. Melanosomes are membrane-bound organelles, 
specialized in the production and distribution of melanin pigment, that are conserved in 
structure from primitive organisms to mammals. However, the nature of this organelle has 
recently been studied in detail using novel techniques for isolation and global proteome 
analysis [16-18]. Those studies shed light on the complex nature of this organelle. As shown in 
Figure 1, melanosomes mature from undifferentiated vesicles (stage I) to elongated vesicles 
containing internal fibrils (stage II). In the presence of specific enzymes such as tyrosinase, 
melanin is synthesized and deposited on the internal fibrils (stage III) of melanosome until they 
become uniformly dense (stage IV) in pigmented cells. Previously, we detailed that this 
maturation process involves the acquisition of several specific proteins that we will call the 
maturation package that stabilizes the organelle for the subsequent maturation steps. As any 
structure, melanosomes build an internal matrix to store melanin in an orderly and efficient 
manner. The internal fibrils identified in stage II melanosomes have been unequivocally 
identified as amyloid aggregates [5;7]. Amyloid fibers derive from a class I transmembrane 
glycoprotein called PMEL that undergoes a series of post-translational modifications that 
involve processing by pro-protein convertases (PC) [5;19;19;20] and glycosylation [12;21] (Figure 
2). These steps are highly regulated and follow an exact succession of processing steps which 
prevents the formation of amyloids during assembly or intracellular trafficking of PMEL. 
Despite evidence that PMEL is a good substrate for PC in melanoma cells, Leonhard and 
coworkers confirmed that PC does not trigger immediate amyloid formation [19]. Our 
evidence suggests that glycosylation is responsible for such protection [12]. Glycosylation of 
proteins involves the addition of N- and/or O-linked oligosaccharide chains to acceptor 
asparagine residues or serine/threonine residues, respectively. N-linked core glycosylation 
begins in the ER, while O-linked glycosylation is a post-translational event which starts in 
the cis-Golgi [22]. PMEL has 5 potential N-glycosylation sites distributed at the N-terminal 
The Role of Glycosylation in the Control of Processing  
and Cellular Transport of the Functional Amyloid PMEL17 329 
(3), RPT (1) and C-terminal (1) domains [12;23]; while O-glycosylation sites have been 
predicted at the repeat sequences of proline, serine, and threonine in the RPT domain [24]. 
 
Figure 1. Melanosome maturation at molecular and morphological levels. The scheme details the 
process of melanosome maturation including variations at the molecular level (drawings) and 
morphological level (images). Note that every stage is characterized by a group of melanosome-specific 
and non-specific proteins. Electron microscopy images show the transformation of this organelle from 
an amorphous, non-pigmented and non-differentiated organelle (stage I) to a well-defined, 
differentiated and pigmented organelle (stage IV). Scheme adapted from [16]. 
 
Figure 2. Scheme of PMEL domains and modification sites. PMEL has only one conserved domain 
called polycystic Kidney disease (PKD) that is located near the center of the protein. During processing, 
the signal domain (SD) is removed early and then PMEL is cleaved (CS) by PC. The N-terminal (NTD) 
and C-terminal (CTD) domains undergo N-glycosylation, while the repeat domain (RPT) undergoes O-
glycosylation. Numbers above the structures indicate the predicted aminoacid position for the N-glycan 
sites; while numbers below the protein graph indicate the aminoacids where each domain 
approximately starts and ends. Scheme adapted from [12].  
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a. N-Glycosylation in PMEL 
The β-glycosylamine linkage of GlcNAc to Asn represents the most widely distributed 
carbohydrate-peptide bond and is the site of attachment for a large variety of complex and 
poly-mannose oligosaccharides in proteins with demonstrated biological importance (See 
[25;26]). A summary of this process is presented in Figure 3.  
 
 
 
Figure 3. N-glycosylation processing in mammalian cells. The scheme details the place and different 
enzymes involved in the post-translational modification of glycoproteins with N-linked 
oligosaccharides. It also includes the different enzymes or steps targeted by different glucosidase 
inhibitors such as castanospermine (CT), deoxynojirimycin (DNJ), deoxymannojirimycin (DMJ), and 
kifunesine (KIF). Note that a series of sialyltransferases (not shown) are in charge of the addition of 
sialic acid at the end of the glycan chains late in the process. Peptide sequence is represented as an 
orange line. Scheme has been modified and adapted from [27].  
In the ER, N-glycosylation starts with the attachment of a core unit of 14 monosaccharide 
residues (Glc3Man9GlcNAc2), which is then processed by the removal of the 3 glucose 
residues attached to the terminal mannose D1 on the α 1-3 arm of the oligosaccharide by α-
glucosidases I and II [27]. In the Golgi, N-glycan processing starts when Man6GlcNAc2 is 
trimmed to Man5GlcNAc2 by Golgi mannosidase I (Figure 3). The extent of N-glycan 
processing towards triantenary and tetraantenary structures is limited by glycosidase 
availability and their accessibility to the processing sites. Noticeably, the enzyme endo-α-D-
mannosidase provides an alternate route for de-glucosylation during a glucosidase blockade 
[27]. To determine the role of N-glycosylation in the processing and the trafficking of PMEL, 
we used several inhibitors that block the modification reactions either in the ER or Golgi 
The Role of Glycosylation in the Control of Processing  
and Cellular Transport of the Functional Amyloid PMEL17 331 
followed by metabolic labeling with [35S] Met/Cys in MNT-1 melanoma cells. We first 
targeted ER glucosidases with either Castanospermine (CT), a competitive inhibitor of α- 
and β-glucosidases, or N-butyl-deoxynojirimycin (NBDNJ), an inhibitor of both 
glucosidases with preference towards glucosidase II[28]. These inhibitors prevent the 
processing of complex glycoproteins and cause the production of immature N-linked 
glycoproteins with Glc3Man7-9GlcNAc2 structure. As detected by αPEP13h (an antibody 
targeting the C-terminal domain of PMEL), treatment with either CT or NBDNJ did not 
affect processing or stability of PMEL. Similar results have been obtained for tyrosinase, a 
key melanin producing enzyme, although it was inactive [28;29]. To confirm the effect of 
this intervention, cells were treated with Endo-H, which removes high mannose/hybrid N-
glycans. Endo H treatment revealed that all forms of PMEL contained immature N-glycans 
sensitive to Endo H (Figure 4A). These results indicate that PMEL, similar to tyrosinase 
[27;30], is not a substrate for Golgi endo-α-mannosidase which is capable of by passing ER 
glucosidases that remove end glucose residues and proceed with the glycosylation process 
in the Golgi. Confocal microscopy analysis revealed that PMEL (red) reaches intracellular 
targets but does not localize to the plasma membrane (Figure 4B). Thus, these results 
suggest that N-glycans may have a limited impact on PMEL processing but may play a role 
in its trafficking to the plasma membrane, possibly for secretion.  
To further verify our results, we blocked the synthesis of complex type N-glycans using a 
fairly potent and specific inhibitors of mannosidase I and α-mannosidase, called 
deoxymannojirimycin (DMJ) and Mannostatin A (ManA), respectively. These inhibitors have 
been extensively studied and have proven to be useful for studying the processing pathway 
and for comparing processing enzymes (For review see [28]). Pre-treatment of melanoma cells 
was followed by metabolic labeling with [35S] Met/Cys for at 3 hrs at 37°C . Consistently these 
inhibitors affected the formation of the mature form of PMEL without affecting cleavage of the 
C-terminal domain. As expected, digestion with Endo H revealed that the resulting “mature” 
PMEL contains non-complex glycans and as such that band was sensitive to this enzyme and 
suggest that this glycoprotein is getting additional modifications independent of N-
glycosylation. These results further suggest that the mature PMEL could be distinguished by 
SDS-PAGE despite it has non-complex modified N-glycans (Figure 5, A and B). We then 
assessed whether PMEL intracellular localization was altered after these conditions in the 
same melanoma cells. To explore this possibility, cells were cultured in the presence of CT and 
ManA for 3 hrs previous to fixation. Confocal microscopy analysis revealed that PMEL (red) 
had a limited distribution in the cytoplasm, mostly perinuclear, compared to HMB-45 (green) 
which is already processed and localized in stage II melanosomes (Figure 5C). Superimposed 
confocal images with DIC showed that treatment did not compromised cell morphology or 
adhesion. Noticeably, PMEL staining was absent nearby the plasma membrane further 
supporting that N-glycosylation plays a role in the distribution of PMEL at the plasma 
membrane. Toxicity and viability assays were performed using different combinations of 
inhibitors and incubation times to determine optical treatment conditions in culture for 
pigmented and non-pigmented melanoma cells (data not shown). 
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Figure 4. Inhibition of N-Glycan maturation does not alter PMEL processing. A. MNT-1 melanoma 
cells were treated for 3hrs with 5 μg/ml of CT, which is known to produce minimal toxicity as reported 
by Takahashi et al.[31], were [35S]-labeled for 30 minutes and chased for the indicated times. Collected 
samples were left undigested or digested with Endo H where noted for 3h at 37 C, after which samples 
were immunoprecipitated with the αPEP13h antibody, which recognize the C-terminal domain of 
PMEL. Immunoprecipitated bands were visualized by autoradiography. Faint bands are indicated with 
either an open arrow (<) or an asterix (*). B. MNT-1 cells were cultured in the presence of 5 mM of 
NBDNJ for 3 hrs prior to fixation with 4% p-formaldehyde. Cells were dual stained either with 
αPEP13h or αPEP25h (red), anti-PMEL antibodies, and vti1b, a Golgi marker (green). Images are 
representative of the staining pattern after three repeated experiments in melanoma cells. Note the 
granular distribution patterns of PMEL. Images are merged with DIC to visualize the unstained parts of 
the melanoma cells. Colocalization of the red and green signals is shown in yellow. Nuclear 
counterstaining was done with DAPI (blue). 
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Figure 5. Complete inhibition of N-Glycan maturation alters the intracellular localization of PMEL. 
A and B. MNT-1 melanoma cells were treated for 3hrs with 5 μg/ml of DMJ or overnight with 50 μg/ml 
of mannostatin A (ManA). Samples were [35S]-labeled for 30 minutes and were chased for the indicated 
times. Collected samples were left undigested or were digested  with Endo H where noted for 3h at 37 
°C, after which samples were immunoprecipitated with the αPEP13h antibody. Immunoprecipitated 
bands were visualized by autoradiography. C. MNT-1 cells were cultured in the presence of both CT 
and ManA for 3 hrs previous to fixation with 4% p-formaldehyde. Cells were dual stained either with 
αPEP13h or αPEP25h (red) and HMB-45 (green). Images are representative of the staining pattern after 
three repeated experiments in melanoma cells. Note limited granular distribution patterns of PMEL 
antibodies, while HMB-45 reactivity seems to be conserved. Images are merged with DIC to visualize 
the unstained parts of the melanoma cells. Colocalization of the red and green signals is shown in 
yellow. Nuclear counterstaining was done with DAPI (blue). 
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To establish a specific role for individual N-glycan sites in PMEL, Hoashi et al., performed 
mutational analysis using several PMEL mutants at the predicted N-glycosylation sites [23]. In 
that study, it was determined that 2 out of 4 N-glycosylation sites were not fully glycosylated 
in Hela cells, which were derived from an adenocarcinoma of the cervix. Consistent with our 
data, the authors concluded that this does not affect PMEL processing but pointed that the 
mutation of the site at S570A altered secretion of PMEL. It is worthwhile to note that a 
glycoform of PMEL is known to be secreted to the extracellular space and in the medium of 
cells in culture [23;32]. However, there is no evidence of amyloid accumulation either in skin 
samples or in skin keratinocytes when co-cultured with normal human melanocytes (JVC, 
unpublished data). One possible reason for this is that PMEL amyloid formation is sensitive to 
pH [7]. Thus, the neutral pH in the extracellular compartment most likely undermines PMEL 
amyloid fiber ability or if any amyloid is formed it is dissolved; while the intra organelle acidic 
pH (5.0) will favor amyloid formation. Interestingly, the secretion of amyloid generating 
proteins has been reported previously for other functional (hormones) and disease-associated 
amyloids [9]. In the case of secreted PMEL, the effects of this activity are still unknown both in 
the context of human skin physiology and melanoma disease progression. Taken all together, 
we conclude that the N-glycosylation of PMEL might influence trafficking to and from the 
plasma membrane while playing a limited role in the protein shedding process and direct 
trafficking to melanosomes in melanocytic cells.  
b. O-glycosylation in PMEL maturation  
Prediction of O-glycosylation sites is not standardized but is known in several proteins as 
linkages in which the sugar is attached to an aminoacid containing a hydroxyl group. 
However, every aminoacid with a hydroxyl functional group (i.e. Serine (Ser), Threonine 
(Thr), Tyrosine (tyr), Hydroxyproline, and Hydroxylysine) has been implicated in that 
process (See details in [25;26]). As summarized in Figure 6, O-glycan structures are 
generated following the action of polypeptide N-acetylgalactosaminyltransferase (GalNAcT) 
enzyme and include 4 common subtypes based on differential monosaccharide linkage 
reactions to the unsubstituted GalNAc (GalNAcα-Ser/Thr). All O-glycans may be modified 
by one of several enzymes to generate different core structures known as core 1, core 2, core 
3, etc. The core 1 O-glycan is generated by the core 1 β3 galactosyltransferase (Gal-T), which 
adds galactose to generate Galβ1-3GalNAcα1-Ser/Thr. This is a key precursor for all core 1 
and 2 mucin-type O-glycans in vertebrates and invertebrates. The biosynthesis of O-glycans 
can be modified and terminated with the addition of sialic acid residues relatively early in 
biosynthesis. For example, certain sialyltransferase enzymes are capable of acting on 
GalNAcα-Ser/Thr, or early O-glycan core subtypes after Core-1-GalT action. These sialic 
acid additions give rise to a series of O-glycan structures that generally restrict further 
biosynthetic steps and have been commonly referred to as tumor-associated (T) antigens. 
In PMEL, the RPT domain has 10 imperfect repeats rich in proline, serine, threonine and 
glutamic acid aminoacids [5;33]. Recognition of this domain in amyloid fibers inside stage  
II melanosomes by the HMB-45 antibody, which recognizes an unknown sialic acid  
structure, suggests that glycan structures in the RPT domain are modified with sialic acid.  
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Figure 6. O-glycosylation process in mammalian cells. The scheme details the different enzymes 
involved in the post-translational modification of glycoproteins with O-linked oligosaccharides. It 
includes the step targeted by the inhibitor benzyl-N-acetyl-α-D-galactosaminide (BG). Note that the 
conformation of O-glycan chains varies in cancer cells compared to normal cells due an early addition 
of sialic acid. Adapted from [37]. 
Previously, we have confirmed that PMEL is modified with sialylated core-1 type O-
glycans in MNT-1 melanoma cells [12]. To assess the role of O-glycosylation in  
PMEL function, we used the sugar analog benzyl-N-acetyl-α-D-galactosaminide (BG), 
known to inhibit O-glycosidation [34-37]. MNT-1 melanoma cells were cultured overnight 
in the presence of 1 to 4nM BG. Immunoblotting analysis revealed that maturation of 
PMEL (upper band) was completely inhibited in a dose dependent manner reaching a 
maximum inhibition at 4 nM (Figure 7A). As expected, HMB-45 staining decreased 
substantially at the doses of 2 nM and 4 nM of BG (Figure XB). Because HMB-45 reactivity 
depends on sialic acid, we then infer that O-glycan structures in PMEL were  
modified with sialic acid. To further confirm this and assess the impact on PMEL stability, 
MNT-1 cells were metabolically labeled with [35S] met/cys and chased at the indicated 
times. As shown in Figure 7B, the mature form of PMEL (white arrow) was inhibited as 
early as 45 min and the stability of PMEL at 90 min. The observed shift in electrophoretic 
mobility following synthesis reflects mainly the loss of negatively charged sialic acid 
residues to O-linked sugars, with the maturation of N-linked chains to hybrid or complex 
forms contributing only slightly to the change in molecular weight. Noticeably, the 
observation of the cleaved 26 kDa band at all time points further suggest that PMEL 
processing by PC is also independent of O-glycan modification. At this point, there is 
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enough evidence to conclude that protein cleavage is independent of post-translational 
glycosylation.  
 
 
 
Figure 7. O-glycosylation is important for proper PMEL maturation. A. MNT-1 melanoma cells were 
cultured in the absence or in the presence of 4 nM BG overnight. Cells were then harvested and cell lysates 
were analyzed using SDS-PAGE. Detection of PMEL was done with αPEP13h or HMB-45 as indicated. 
Actin was used as a loading control. B. After treatment with BG overnight, samples were [35S]-labeled for 
30 min and then chased for the indicated times. Collected samples were immunoprecipitated with the 
αPEP13h antibody. Immunoprecipitated bands were visualized by autoradiography. Arrows next to 
PMEL bands represent: mature PMEL (white), cleaved (grey), intermediate (black).  
c. Sialylation in PMEL 
The negatively charged residues of sialic acid exert a particular influence on the  
3 dimensional structure of the protein backbone. Sialic acid can be added to complex N- and 
O- linked glycans preferentially in α2,3 and α2,6 linkages to a penultimate galactose residue 
[38;39]. The transfer of these residues is catalyzed by several enzymes known  
as sialyltransferases (ST). To examine the impact of sialic acid addition to N- and O-glycan 
chains in PMEL, we transfected full length PMEL into wild-type and mutant Chinese 
hamster ovary (CHO) cells that exhibit a specific glycosylation defect. These  
cells provide an excellent tool to study the role of individual sugar residues in protein 
processing. Thus, the outcome of the glycoproteins could be predicted and it is summarized 
in Figure 8. 
To test whether sialic acid addition affects the PMEL amyloid formation ability, we 
transfected full length PMEL into wild type- and mutant- (Lec1, Lec2 and Lec8) CHO cells. 
The Lec1 mutant is a leuco-phytohemagglutinin resistant cell line unable to synthesize 
complex and hybrid N-glycans due to the lack of N-acetylglucosaminyltransferase I 
(GnTI) activity [40]. The Lec2 mutant has a deletion mutation in the CMP-sialic acid 
transporter resulting in N- and O-glycans with a greater than 90% decrease in sialic acid 
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content [41]. The Lec8 mutant has a deletion mutation in the UDP-galactose transporter 
resulting in a truncated protein with a greatly reduced ability to translocate UDP-
galactose (UDP-Gal) inside the Golgi [42]. Thus, Lec8 cells generate non-galactosylated 
and non-sialylated N- and O-glycans. Immunoblotting analysis showed PMEL was 
successfully expressed in these cell lines. Noticeably, PMEL was correctly processed in all 
mutant cells showing a band pattern that was no different than those in melanoma cells, 
except for minor differences in the molecular weight of the mature PMEL (white arrow) 
which reflects the different glycosylation background of the host cells (Figure 9). We 
noted that the mature PMEL (white arrow) band intensity is stronger in wild-type CHO 
cells than that observed in melanoma cells and in melanocytes. On the contrary, this same 
band in the absence of sialic acid modification is undefined despite correct modification 
with core 1-O-glycans in Lec2 cells.  
 
 
 
 
 
 
 
 
 
 
Figure 8. Scheme detailing the specific mutation and the affected step in glycosylation processing. 
Summary of the outcomes for N- and O-glycans expected from the different CHO cell mutants (Lec1, 
Lec2 and Lec8) Adapted and modified from [41]. 
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Figure 9. PMEL expression in CHO cells results in different glycoforms. A V5-His 6 tag full length 
PMEL was transiently transfected into the indicated cells lines. At 48 hr post-transfection, cells were 
harvested and lysates were analyzed by immunoblotting. PMEL was detected using the αPEP13h 
antibody. Lysates from normal human melanocytes from black donors (NHMB) and from MNT-1 
melanoma cells were used as controls for the PMEL band pattern. Arrows next to PMEL bands 
represent: mature PMEL (white), cleaved (grey), intermediate (black).  
These results suggest that the band shifts in the mature PMEL band mainly reflect either the 
addition or loss of sialic acid residues. Previous reports have focused on the band size and 
location to infer about the maturation state of PMEL [20;23]. However, our results clearly 
indicate that PMEL shares a similar band pattern in all transfected cell lines despite the 
different N- and O-glycan composition. In other words these band patterns represent 
glycoforms of PMEL. Glycoform is a term that indicates differences in the composition of 
the glycan chains derived from an identical backbone protein [25;26;43]. This phenomenon 
is also known as microheterogeneity. From the practical point of view, microheterogeneity 
explains the anomalous behavior of glycoproteins in various forms of chromatography 
(such as the diffuse bands observed on SDS-PAGE gels) and makes the complete structural 
analysis of most ‘glycoproteins a difficult task. From a functional point of view, the meaning 
of this heterogeneity remains unclear. It is possible that this is a type of "diversity generator" 
intended either to diversify endogenous recognition functions and/or to evade detection 
after malignant transformation. Interestingly, we reported that the amyloid formation 
abilities of PMEL were altered in vivo at different levels depending on the glycosylation 
defect [12]. Thus, lack of sialic acid resulted in the accumulation of thick amyloid fibers (Lec 
2 cells), while the lack of the end terminal galactose modified with sialic acid at core-1-O-
glycans resulted in complete loss of amyloid fibrils at target organelles (Lec 8 cells). Thus, 
these results indicate that mature PMEL is mainly formed by O-glycan derived-structures 
and the loss of this modification decreased PMEL stability in melanoma cells. 
There have been several reports indicating that changes in sialylation patterns correlate with 
changes in cell motility and invasiveness [44-47]. In melanoma, it has been shown that 
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adhesion molecules such as N-cadherin and integrins undergo altered glycosylation and 
sialic acid modification [48-51]. Thus, we hypothesize that melanoma cells may exhibit 
altered sialyltransferase (ST) activities compared to either melanocytes or other cell lines 
that affects the glycosylation pattern of most proteins, including PMEL. Analysis of 
sialyltransferase activity in MNT-1 melanoma cells compared to normal human melanocytes 
(NHM) using different glycoproteins as acceptor substrates confirmed differences between 
these cell lines. As shown in Figure 10, both cell lines exhibited sialyltransferase activity 
towards asialofetuin, which bear unsialylated N-glycans and unsialylated core 1 O-glycans, 
although MNT-1 cells were less active than NHM. In contrast, very high levels of 
sialyltransferase activities were detected using fully sialylated fetuin as acceptor (Figure 
10A), showing that these cells can substitute sialic acid on already sialylated carbohydrates 
an ability known as oligo- or poly-sialylation [52]. Thus, NHM is 5 times more active than 
MNT-1 and 25 times more active than the breast cancer cell line T47-D, used as a control, in 
the addition of sialic acid to glycan chains. Using real-time PCR, we confirmed that the 
mRNA levels for α2,3-sialyltransferase (ST3 GalNacI) and α2,6-sialyltransferase (ST6 
GalNac II) were higher in melanocytes, which correlated with the increased ST activity 
detected in these cells. Furthermore, we reported that melanocytes preferentially add sialic 
acid to O-glycans while melanoma cells do it without specific preference, although in a less 
active fashion [12]. Thus, our results prove that there are cell-specific differences related to 
addition of sialic acid to the ends of both N- and O-glycans. 
 
 
Figure 10. Melanocytes exhibit increased ability to transfer sialic acid to glycans. A. Sialyltransferase 
activity against the acceptor substrates asialofetuin or fetuin measured in lysates of normal human 
melanocytes from black donors (NHMB) or MNT-1 melanoma cells; values are expressed as total 
counts/min of 14C against μg of protein. B. Real-time PCR mRNA expression of ST3 GalNac I and ST6 
GalNac II enzymes in NHMB and the human cancer cell lines, MNT1 (melanoma) and T47D (breast). 
Values are expressed in transcript units related to actin. PCR primer sequences have been reported in 
Valencia et al., [12].  
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Lectins are sugar-binding proteins (not to be confused with glycoproteins, which are 
proteins containing sugar chains or residues) that are highly specific for their sugar moieties. 
They play a role in biological recognition phenomena involving cells and proteins. Lectins 
have a multimeric structure, which is responsible for the ability to agglutinate cells or form 
precipitates glycoconjugated in a manner similar to antigen-antibody interactions. During the 
past few years, lectins that discriminate between various types of sialylated sequences have 
been reported [53]. The lectin from elderberry (Sambucus nigra) bark (SNA I) has been shown 
to bind with high affinity to glycoconjugates containing the terminal sequence sialic acid α2,6-
galactose/N-acetylgalactosamine. Similarly, the leukoagglutinin from Maackia amurensis 
(MAL) binds with high affinity to sialic acid α2,3 galactose β1,4 N-acetylglucosamine but not 
to 2,6-linked isomers and, therefore, is a most interesting complementary probe to the SNA 
[53]. To more specifically determine the most frequent sialic addition related with PMEL, we 
performed a detail cytochemical analysis of the distribution of α2,6- and α2,3- linked sialic acid 
residues using MAL and SNA I in MNT-1 melanoma cells (Figure 12). Confocal microscopy 
dual immunofluorescence revealed that PMEL (red), as detected by αPEP13h or HMB-45 
antibodies, colocalized more frequently with MAL (green) in the cytoplasm of melanoma cells 
(Figure 12,A-C). Specifically, the staining pattern of HMB-45 antibody colocalized almost 
exclusively with MAL (Figure 12, D-F) suggesting that the α2,3 addition is more likely 
recognized by this antibody. These result also suggest that α2,3 is the most frequent 
modification in the glycan chains of PMEL. On the other hand, SNA staining was limited to 
the plasma membrane where it colocalized with PMEL (Figure 12, G-I) suggesting that plasma 
membrane forms of PMEL, including the secreted PMEL glycoform, are more likely to be 
modified with α2,6 instead of α2,3 terminal sialic acids ends.  
In melanoma cells, immunopurified forms of PMEL show that N-glycosylation sites located 
at the N- and C-terminal domains were modified with sialic acid [12]. Detection of 
unsialylated N-glycan chains is an indication of the predominantly hybrid nature of the 
structures in PMEL. This type of variability opens the possibility that at least two 
glycoforms of PMEL are produced in one cell type or in cell lines from the same lineage. To 
effectively prove that PMEL glycan chains are differentially managed in a cell-specific 
manner, lysates from different melanoma cell lines and NHM were digested with a 
combination of the following enzymes: α2,3,6,8,9 neuroaminidase, β1,4 galactosidase, β-N-
acetylglucosaminidase known to remove complex and hybrid structures (Figure 13). As 
detected by the anti-PMEL antibody αPEP13h, enzyme digestion rendered new bands that 
migrated different between cell lines, specially between melanoma cells and melanocytes. 
Thus, all cells exhibited bands of around 85 kDa and 20 kDa after the combined enzyme 
digestion (red arrows). These new bands are composed by non-complex unsialylated N- and 
O-glycans. Interestingly, the band patterns of pigmented cells (NHM, MNT-1 and UACC-
257) were somewhat different than those in non-pigmented cells (SK-Mel-28 and M14). The 
only consistency was the minor molecular shift of the cleaved band at 26 kDa suggesting 
that post-translational modification of this domain in PMEL was similarly modified 
independent of the cell type. These results confirm that the majority of N-glycans on this 
band are hybrid not complex type.  
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Figure 11. Immunohistochemical distribution of α2,3 and α2,6 sialic acid additions in MNT-1 
melanoma cells. MNT-1 cells were grown in Lab TeK II chamber slides with cover at a density of 1 X104 
cells per chamber. After 48hrs, cells were fixed with 4% p-formaldehyde and dual stained either with 
αPEP13h or HMB-45 (red) and the lectins MAL or SNA (green). Images are representative of the 
staining pattern after three repeated experiments in melanoma cells. Note the granular distribution 
patterns of PMEL antibodies and MAL that differ from the predominantly plasma membrane 
distribution of the lectin SNA. Colocalization of the red and green signals is shown in yellow. Nuclear 
counterstaining was done with DAPI (blue).  
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Figure 12. PMEL is differently glycosylated in human melanoma cells compared to melanocytes. 
Lysates from indicated cell lines were digested in the presence or absence of the enzymes noted and 
were analyzed by SDS-PAGE. Samples were separated on a 4-20% Tris glycine gels for 2 hr. Arrows 
next to PMEL bands represent: mature PMEL (white), cleaved (grey), intermediate (black), digested 
bands (red). 
d. Glycosylation enzymes in melanosomes 
Previously, we made possible global melanosome proteome characterization by using 
LC/MS to analyze both non-pigmented (pre-melanosomes) and pigmented melanosomes in 
solution digest after removal of melanin by immobilized metal affinity chromatograpy 
(IMAC) [16;17]. Briefly, we took advantage of the heavy metal ion sequestering property of 
melanin by loading the resulting peptides onto an IMAC column activated with an excessive 
volume of FeCl3, assembled back-to-back with a reverse-phase (RP) precolumn. The 
melanin was retained on the IMAC column due to the high affinity of Fe (III) for the o-diOH 
groups of melanin, while the peptides passed through and were subsequently caught on the 
C18 RP-precolumn. This assembly allowed the efficient and concurrent removal of melanin 
and the loading of the sample onto the column in a single step prior to the LC/MS analysis. 
Thus, proteomic analysis of melanosomes required an effective approach for purifying and 
solubilizing them, and removing the melanin.   
Arrival of PMEL to melanosomes initiates a well coordinated sequence of events to 
incorporate and shred the protein into smaller pieces to expose the RPT domain and start 
the formation of amyloid fibers. Several reports agree that this process is initiated by a series 
of PC [19;54]. After that process, we hypothesized that the sialylated O-glycans covering the 
RPT domain of PMEL must be removed before amyloid formation. This is what we propose 
as the protective role these glycans exert in the amyloid processing. To perform such task, 
melanosomes will have to be equipped with enzymes specialized in the removal of 
carbohydrate modifications, such as sialyltransferases or hexosaminidases. To evaluate 
whether or not this is possible, we analyzed our proteome database for the presence of 
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enzymes involved in the modification of glycan chains. As shown in Table 1, there were 
several enzymes involved in either the transfer of sialic acid (like α2,6 ST), removal of fucose 
(another terminal modification of N- and O-glycan products), or removal of carbohydrates 
such as glucose (α-glucosidase II, glucosidase I), mannose (mannosidase) and galactose 
(GalNAc-T2). Many of these enzymes have been identified to localize throughout the Golgi 
cisternae like GalNac-T2 or T3. Note that most of these enzymes were identified in early 
maturation stages of melanosomes (stage I and II), not the fully mature late stage, of the 
pigmented MNT-1 and non-pigmented SK-Mel-28 cells. Interestingly, there is evidence that 
the localization of these enzymes is highly variable not only with respect to their normal 
localization inside the Golgi stack [55;56], but also in ectopic Golgi sites including the 
plasma membrane (see review [57]).  
 
Protein 
AC 
Protein
ID 
Group Protein Name 
Q9H553 ALG2 
MNT1_stage2 
MNT1_stage2 
Alpha-1, 3-mannosyltransferase ALG2 (EC 2.4.1.-) 
(GDP- Man:Man(1)GlcNAc(2)-PP-dolichol 
mannosyltransferase 
Q9BTY2 FUCO2 MNT1_stage1 
alpha-L-fucosidase precursor (EC 3.2.1.51) (Alpha-L-
fucosidase 2) (Alpha-L-fucoside fucohydrolase 2) 
Q96L58 B3GT6 Skmel28_stage1 
Beta-1, 3-galactosyltransferase 6 (EC 2.4.1.134) (beta 
3GalT6) (Galactosylxylosylprotein 3-beta-
galactosyltransferase) (Galactosyltransferase II) 
(GAG GalTII) 
Q92685 ALG3 
Skmel28_stage1; 
Skmel28_stage2; 
uniqueSkmel28 
Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl 
mannosyltransferase (EC 2.4.1.-) (Dol-P-Man-
dependent alpha(1-3)-mannosyltransferase) 
Q16739 CEGT 
MNT1_stage 1 
and 2; 
Skmel28_stage1; 
Skmel28_stage2; 
common_earlysta
ge 
Ceramide glucosyltransferase (EC 2.4.1.80) 
(Glucosylceramide synthase) (GCS) (UDP-
glucose:N-acylsphingosine D-glucosyltransferase) 
(UDP- glucose ceramide glucosyltransferase) 
(GLCT-1) 
Q14697  GANAB
MNT1_stage1,2, 
and 4; Skmel28_ 
stage1; 
Skmel28_stage2; 
common_early_ 
stage 
Neutral alpha-glucosidase AB precursor (EC 
3.2.1.84) (Glucosidase II subunit alpha) 
Q14435 GALT3 Skmel28_stage1 
Polypeptide N-acetylgalactosaminyltransferase 3 
(EC 2.4.1.41) (Protein-UDP 
acetylgalactosaminyltransferase 3) (UDP- 
GalNAc:polypeptide N-
acetylgalactosaminyltransferase 3) (Polypeptide 
GalNAc transferase 3) (GalNAc-T3) (pp-GaNTase 3) 
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Protein 
AC 
Protein
ID 
Group Protein Name 
Q13724  GCS1 
MNT1_stage1; 
Skmel28_stage2 
Mannosyl-oligosaccharide glucosidase (EC 
3.2.1.106) (Processing A- glucosidase I) 
Q10471  GALT2 Skmel28_stage1 
Polypeptide N-acetylgalactosaminyltransferase 2 
(EC 2.4.1.41) (Protein-UDP 
acetylgalactosaminyltransferase 2) (UDP- 
GalNAc:polypeptide N-
acetylgalactosaminyltransferase 2) (Polypeptide 
GalNAc transferase 2) (GalNAc-T2) (pp-GaNTase 2) 
P34059  GA6S 
NG; 
Skmel28_stage1 
N-acetylgalactosamine-6-sulfatase precursor (EC 
3.1.6.4) (N- acetylgalactosamine-6-sulfate sulfatase) 
(Galactose-6-sulfate sulfatase) (GalNAc6S sulfatase) 
(Chondroitinsulfatase) (Chondroitinase) 
P15907  SIAT1 Skmel28_stage1 
CMP-N-acetylneuraminate-beta-galactosamide-
alpha-2,6-sialyltransferase (EC 2.4.99.1) (Beta-
galactoside alpha-2,6-sialyltransferase) (Alpha 2,6-
ST) (Sialyltransferase 1) (ST6Gal I) 
P15586  GL6S 
MNT1_stage 1,2,4; 
commonMNT1; 
unique MNT1 
N-acetylglucosamine-6-sulfatase precursor (EC 
3.1.6.14) (G6S) (Glucosamine-6-sulfatase) 
P07686  HEXB 
MNT1_stage4; 
NG; 
Skmel28_stage1; 
Skmel28_stage2;  
Beta-hexosaminidase beta chain precursor (EC 
3.2.1.52) (N-acetyl-beta- glucosaminidase) (Beta-N-
acetylhexosaminidase) (Hexosaminidase B) 
(Cervical cancer proto-oncogene 7) (HCC-7) 
P06865  HEXA 
MNT1_stage1; 
Skmel28_stage1;  
Beta-hexosaminidase alpha chain precursor (EC 
3.2.1.52) (N-acetyl- beta-glucosaminidase) 
(Hexosaminidase A) 
O94766  B3GA3 Skmel28_stage1 
Galactosylgalactosylxylosylprotein 3-beta-
glucuronosyltransferase 3 (EC 2.4.1.135) (Beta-1,3-
glucuronyltransferase 3) (Glucuronosyltransferase-I) 
(GlcAT-I) (UDP-GlcUA:Gal beta-1,3-Gal-R 
glucuronyltransferase) (GlcUAT-I) 
O60701 UGDH 
Skmel28_stage1 
Skmel28_stage1 
UDP-glucose 6-dehydrogenase (EC 1.1.1.22) (UDP-
Glc dehydrogenase) (UDP-GlcDH) (UDPGDH) 
O00754  MA2B1 
MNT1_stage1; 
MNT1_stage4; 
Skmel28_stage1;  
Lysosomal alpha-mannosidase precursor (EC 
3.2.1.24) (Mannosidase, alpha B) (Lysosomal acid 
alpha-mannosidase) (Laman) (Mannosidase alpha 
class 2B member 1 
Source: Full database access could be found at http://pir.georgetown.edu/iproxpress/melanosome/suppl_data/.  
For details of the database features please refer to [16;17]  
Table 1. List of glycosylation enzymes identified in the proteome of melanosomes 
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Despite these initial data, we should consider that the identification of these enzymes in 
melanosomes might be due to contamination of the purified melanosome sample. A crucial 
issue in proteomic analysis of subcellular proteomes is the ability to distinguish between 
true components and contaminants coming from other cell compartments, especially when 
working with low abundance proteins. Interestingly, except for known melanosome 
proteins that give the organelle its unique structure and functions, a majority of proteins 
detected in the melanosome proteome are not organelle-specific. Some, such as ribosomal 
protein complexes, are obvious minor contaminants that were co-purified during sucrose 
gradient fractionation. Even though extra precaution was taken, sensitive mass 
spectrometers can always detect trace amounts of peptides that originate either from 
resident low abundance proteins or from low-level contaminants. By searching our data 
against known human mitochondrial proteins annotated in UniProtKB, we estimate that the 
melanosome fractions at various stages are of high purity (94 % at early stage, and 98-99% at 
late stage). On the other hand, many proteins identified in our study demonstrate that 
melanosomes are highly dynamic. They may be viewed as a microcosm of organelles, 
representing a dynamic balance of proteins as well as small molecules being transported in 
and out. Many of the “nonspecific” proteins might be associated with melanosomes only for 
a short period of time, or they may be proteins that reside in other subcellular 
compartments. In that sense, we considered the possibility that true permanent “resident” 
molecules for organelles may not exist. Because of the uniqueness of melanosomes our 
study has become the gold-standard for future analysis. Taken all together, it is feasible that 
certain enzymes relocate to early melanosomes and become involved in the removal of 
glycan chains from PMEL to start the amyloid formation process. Further studies will be 
necessary to convincingly answer this question.    
3. Conclusions and future directions  
We suggest that the dynamics of amyloid formation could be managed or restored by jointly 
manipulating protein synthesis, N- and O-glycosylation, and Golgi remodeling. In the case 
of PMEL, we believe that the main role of glycosidation is to avoid the early start of the 
amyloid formation process in non-suitable intra or extra cellular locations. Thus, the sialic 
acid modified core-1-Oglycans in the RTP domain protect this domain from early protein 
shredding. The influence of glycosylation can be attributed to both the steric demand of the 
sugar moiety and hydrogen bonding, respectively. First, the incorporation of a single or a 
series of sugars will increase the serine side-chain volume dramatically, which results in a 
tight packing interaction which disrupts protein self-assembly into fibrils and prevents the 
exposure of this domain. The reported finding that the N-glycan site at aminoacid 321, 
located in the RPT domain of PMEL, is minimally modified indirectly supports this notion 
[12;33]. However, carbohydrate hydroxyl groups can still be involved in hydrogen bonding 
and sugar competition for intermolecular hydrogen bonds and could have an effect on the 
overall integrity of the structure. To avoid this situation, sialic acids are added at the non-
reducing ends of glycans, conferring strong negative charges on the protein. We predicted 
that sialic acid when added to N-glycans makes then hydrophilic and leads to exposure of 
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hydrophobic protein domains, as occurs during cleavage of PMEL, favoring the formation 
of polymers through hydrophobic interactions. In contrast, sialic acid added to O-glycans 
make them hydrophobic and protects them from early cleavage and degradation, a function 
that has been reported previously in other cells [12;33;58;58]. Thus, the extent and type of O-
glycans modified with sialic acid in the RPT domain of PMEL play key roles to determine 
the proper PMEL glycoform destined to form fibrils [59], or to be targeted to the plasma 
membrane [60; 61] 
In light of the presented evidence, it is critical to understand that cancer cells present altered 
glycosylation patterns compared to their normal counterparts and that it will impact all 
glycoproteins. This is the case in murine melanoma cells, the interaction of cell surface 
lectins (such as calreticulin [62]) that bind proteins modified with mannose type glycans are 
necessary to initiate the increases of murine melanoma [63]. Similarly, the expression of 
high-mannose type glycans increases the development of hepatic metastasis in B16 
melanoma cells [64] or that high-mannose type glycans are also involved in the functionality 
and cell surface expression of the “mature” human transferrin receptor [65;66]. Furthermore, 
differences in the patterns of expression of sialyltransferases, such as ST3 Gal I, between 
normal and malignant cells had already been associated with a cancer-specific regulation of 
glyco-epitopes [67]. Therefore, it is not unusual that “mature” proteins contain unmodified 
mannose-rich/ hybrid type N-glycans and that such conformation plays an active role in 
cellular processes. On the contrary, these findings reveal a new factor to consider in the 
processing of cancer-specific proteins, especially in Melanomas. Future research should be 
aimed to understand in depth and consider these alternatives. 
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